New portfolio pick: RadNet, Inc. (NASDAQ: RDNT) is being added to the Healthcare Innovation Portfolio as a differentiated healthcare technology idea combining a scaled outpatient imaging network with a growing AI-enabled digital health platform.
Why RadNet Fits the Healthcare Innovation Theme
RadNet is best known as a large U.S. outpatient diagnostic imaging operator, but the more interesting portfolio angle is its DeepHealth digital health segment. DeepHealth develops radiology informatics and AI tools across breast, lung, prostate and other imaging workflows, giving RadNet both a recurring software growth option and a controlled real-world imaging network for deployment.
This makes RDNT a useful diversifier versus the portfolio’s existing diagnostics, robotic surgery, sleep-apnea, organ-transplant and healthcare-services technology holdings. The stock adds exposure to outpatient imaging utilization, AI radiology workflow adoption, screening expansion and health-system partnership growth.
Investment Thesis
RadNet screens well on risk-adjusted upside because it is not a pre-revenue AI story: the company has a scaled operating base, positive adjusted EBITDA, significant cash, and a fast-growing Digital Health segment. In Q2 2026, RadNet reported record quarterly revenue and adjusted EBITDA, raised 2026 imaging-center guidance, and reported Digital Health annual recurring revenue of $105.5 million, up from $53.5 million a year earlier.
The core bet is that investors increasingly value RadNet as a hybrid healthcare infrastructure and AI software platform rather than only as an imaging-center consolidator. If imaging-center demand remains firm and DeepHealth continues to convert FDA-cleared products into commercial ARR, the stock has a credible path to further rerating over the next 6 to 12 months.
Key 12-Month Catalysts
- Raised 2026 guidance execution: management increased full-year Imaging Center segment guidance after Q2, including revenue of $2.37 billion to $2.42 billion, adjusted EBITDA of $345 million to $358 million, and free cash flow of $115 million to $125 million.
- DeepHealth ARR growth: Digital Health revenue grew more than 50% year over year in Q2 2026, while ARR nearly doubled year over year to $105.5 million, giving the market a tangible software metric to track.
- FDA-cleared product expansion: DeepHealth received 2026 FDA clearances for new AI breast-suite capabilities and an AI-powered breast ultrasound solution, expanding its commercial product set.
- Balance-sheet flexibility for growth: RadNet reported $726.3 million of cash at June 30, 2026 and a 1.8x net debt to adjusted EBITDA ratio, while also adding a $250 million incremental term loan intended for acquisitions, organic expansion and health-system partnerships.
Valuation View
RDNT is not a statistically cheap small-cap. With a recent market capitalization around $5.9 billion and enterprise value around $7.4 billion, the stock already discounts meaningful execution. However, the premium valuation is partly supported by double-digit imaging growth, positive free-cash-flow guidance, and the potential for DeepHealth to earn a higher software-style multiple if ARR growth remains strong. The risk-adjusted opportunity is attractive because the downside is cushioned by an operating healthcare-services business, while the upside comes from AI radiology adoption and continued guidance upgrades.
Balance Sheet and Survivability
RadNet has leverage, but the balance sheet appears survivable rather than distressed. As of June 30, 2026, the company reported $726.3 million in cash and cash equivalents, no outstanding balance on its Barclays revolving credit facility, and a net debt to adjusted EBITDA ratio of 1.8x. Total debt, including finance lease liabilities, was about $1.34 billion, so interest-rate exposure and acquisition discipline remain important watch items.
Key Risks
- Reimbursement and utilization risk: changes in imaging reimbursement, payer behavior, Medicare policy, referral patterns or patient volumes could pressure revenue and margins.
- Valuation and AI-execution risk: the stock already reflects high expectations; if DeepHealth ARR growth slows, product adoption disappoints, or R&D spending delays margin expansion, the multiple could compress.
Bottom Line
RadNet is the preferred new Healthcare Innovation Portfolio pick because it offers a rare combination of healthcare AI optionality, near-term earnings visibility, raised guidance, recurring digital health revenue growth and balance-sheet capacity. For the next six months, the best setup is continued proof that DeepHealth is becoming a scalable AI radiology platform on top of a growing imaging network.
Risk disclaimer: This content is for informational and research purposes only and is not personalized investment advice. Equity investments can lose value, and investors should conduct their own due diligence.